Phase 3 N=246 Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear
Ametropia
Primary: Best Corrected Visual Acuity — 0.65; 1.33; 98.06; 98.67 Percentage of Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=304 Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.
Schizoaffective Disorder · Psychotic Disorder
Primary: Positive and Negative Symptoms of Schizophrenia (PANSS) Total Score at Baseline. — 91.7; 92.3 points on a scale — p=0.774
Phase 3 N=348 Comparison of NPH Insulin and Insulin Detemir in Children and Adolescents With Type 1 Diabetes
Diabetes · Diabetes Mellitus, Type 1
Primary: Glycosylated Haemoglobin A1c (HbA1c) — 8.75; 8.64 Percent (%) glycosylated haemoglobin
Phase 3 N=862 Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus
Staphylococcal Skin Infection
Primary: Clinical Response — 323; 321; 52; 58 participants
Phase 3 N=761 Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus
Bacterial Pneumonia
Primary: Clinical Response — 214; 221; 46; 68 participants
Phase 3 N=475 A Phase III Trial For Patients With Metastatic Breast Cancer
Breast Cancer · Breast Neoplasms · Cancer of the Breast
Primary: Time to Disease Progression (Initial Treatment) — 9.28; 8.88 months — p=0.385
Phase 3 N=310 A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia
Mixed Dyslipidemia
Primary: Percentage of Subjects Reporting Adverse Events During Combination Therapy in the Preceding Double-Blind Studies or in the Preceding Open-Label Year 1 Study or in This…
Phase 3 N=9,779 Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane
Breast Neoplasms
Primary: Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 2.75 Years — 352; 388 Events (disease relapse or death) — p=0.118
Phase 3 N=22 Study to Determine the Anti-plaque Efficacy of Commerical Toothpastes and an Oral Rinse
Dental Plaque
Primary: Plaque Index — 3.31; 3.31; 2.91 Units on a scale — p=0.05
Phase 3 N=462 A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
Benign Prostatic Hyperplasia
Primary: Measuring Change From Baseline in International Prostate Symptom Score (IPSS) at 12 Weeks — 21.2; 21.2; -6.3; -3.4 Units on a scale
Phase 3 N=154 Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Participants With Asthma (0476-911)
Exercise Induced Asthma
Primary: Maximum Post-exercise Percent (%) Fall in FEV1 — 10.57; 13.82 Percent change from baseline — p=0.009
Phase 3 N=504 Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).
Smoking Cessation
Primary: Number of Subjects With Four Week Continuous Quit Rate (CQR) — 105; 22 participants — p=<0.0001
Phase 3 N=461 A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
Benign Prostatic Hyperplasia (BPH)
Primary: International Prostate Symptom Score (IPSS) — 21.5; 21.4; -6.5; -3.6 Units on a 0 to 35 scale
Phase 3 N=103 Albuterol HFA MDI in Pediatric Participants With Asthma
Asthma
Primary: Maximum Percent Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Observed up to Two Hours Post Dose (FEV1max%0-2) on Day 22 — 12.849; 9.353…
Phase 3 N=374 BAY12-8039: 5 Days for Sinusitis vs Placebo
Sinusitis
Primary: Percentage of Subjects With Clinical Cure (Modified Intent-to-Treat (MITT)) — 78.1; 66.7; 19.2; 33.3 Percentage of subjects — p=0.189